Details of the Drug

General Information of Drug (ID: DMF5794)

Drug Name

URO-902

Indication

Disease Entry	ICD 11	Status	REF
Overactive bladder	GC50.0	Phase 2	[1]
------------------------------------------------------------------------------------

Drug Type

Gene therapy

Cross-matching ID

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Calcium-activated potassium channel KCa1.1 (KCNMA1)	TTE87WJ	KCMA1_HUMAN	Not Available	[2]

------------------------------------------------------------------------------------

Molecular Interaction Atlas (MIA)

Jump to Detail Molecular Interaction Atlas of This Drug

Molecular Expression Atlas of This Drug

The Studied Disease

Overactive bladder

ICD Disease Classification

GC50.0

Molecule Name	Molecule Type	Gene Name	p-value	Fold-Change	Z-score
Calcium-activated potassium channel KCa1.1 (KCNMA1)	DTT	KCNMA1	4.48E-03	0.19	0.7

Molecular Expression Atlas (MEA)

Jump to Detail Molecular Expression Atlas of This Drug

References

1	ClinicalTrials.gov (NCT04211831) An Exploratory Phase 2a Study Evaluating the Efficacy and Safety of URO-902 in Subjects With Overactive Bladder and Urge Urinary Incontinence. U.S.National Institutes of Health.
2	Evaluating the safety and potential activity of URO-902 (hMaxi-K) gene transfer by intravesical instillation or direct injection into the bladder wall in female participants with idiopathic (non-neurogenic) overactive bladder syndrome and detrusor overactivity from two double-blind, imbalanced, placebo-controlled randomized phase 1 trials. Neurourol Urodyn. 2020 Feb;39(2):744-753.